10d, a Pyridoquinoxaline-Based P-Glycoprotein Inhibitor, Exacerbates MPTP-Induced Neurotoxicity in PC12 Cells.

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Efflux pumps are essential components of cellular detoxification mechanisms, regulating the intracellular accumulation of xenobiotics and endogenous compounds. Among them, P-glycoprotein (P-gp) plays a role in protecting the brain from potentially toxic molecules, and alterations in its function have been associated with neurodegenerative disorders, including Parkinson's disease (PD). Although P-gp inhibitors have been extensively investigated in the context of multidrug resistance, their effects on neuronal cells remain poorly characterized. In the present study, we investigated the biological effects of the pyridoquinoxaline-based efflux pump inhibitor 2,2'-(pyrido[2,3-g]quinoxaline-2,3-diylbis(methylene))bis(oxy)bis(N-phenylbenzamide) (10d) in PC12 cells, a widely used dopaminergic neuronal model. The effects of 10d were evaluated by an MTT-based cell viability assay, while intracellular and extracellular dopamine (DA) levels and DA metabolites were quantified by high-performance liquid chromatography (HPLC). In addition, the ability of 10d to modulate MPTP-induced neurotoxicity was assessed, alone and in combination with amantadine (AMA), a known antiparkinsonian drug. Exposure to 10d (5 and 10 μM) reduced PC12 cell viability and markedly enhanced MPTP-induced cytotoxicity. Furthermore, 10d altered dopaminergic homeostasis by decreasing intracellular DA levels and modifying DA metabolite profiles, with more pronounced effects following co-treatment with MPTP. The combined administration of 10d, MPTP and AMA produced a stronger disruption of DA metabolism compared with individual treatments or 10d/MPTP co-exposure.

Related topics